Petra Vayne-Bossert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Petra Vayne-Bossert has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Janet Hardy
Mater Research Institute The University of Queensland, South Brisbane, Queensland, Australia
3 shared publications - Sophie Pautex
Geneva University, Geneva, Switzerland
3 shared publications - Karyn Foster
Mater Research Institute The University of Queensland, South Brisbane, Queensland, Australia
2 shared publications - Phillip Good
Department of Palliative Care St Vincent's Private Hospital Brisbane Brisbane Queensland Australia
2 shared publications Adam D Ewing
Mater Research Institute The University of Queensland, South Brisbane, Queensland, Australia
1 shared publicationAlexandrine Bruchard
Infirmière, EHPAD du Salève, Cruseilles
1 shared publication
Latest Publications
- 18 December 2025
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 16 (2) , 393-400
Genomic variation in symptom expression in castrate-resistant prostate cancer
Objectives: Men with castrate-resistant prostate cancer (CRPC) suffer from symptoms related to both their disease and its treatment with marked variation between individuals with respect to symptom expression. This study aimed to determine whether genetic variation in cytokine expression is associated with symptom severity. Methods: An exploratory prospective, longitudinal consecutive patient cohort study was undertaken across two Queensland sites. Patient characteristics including tumour burden and current treatment were collected at baseline. Symptom severity was assessed 3–4 weekly for up to 6 assessments, with blood taken for genetic analysis once only during the study. Cytokine gene variants of each participant were assessed using a panel of single nucleotide polymorphisms (SNPs) most described in the literature. Results: Of the 66 participants, 27/66 (41%) had a low, and 39/66 (59%) a high tumour burden. Symptom severity was not related to tumour burden or patient characteristics. Of the 142 SNPs analysed from 62 participants, 15 SNPs from 7 genes were significantly associated with symptom severity. After Benjamini-Hochberg adjustment, SNPs rs2069772 from Interleukin-2 (IL2) and rs230494 from Nuclear Factor kappa-light-chain-enhancer of activated B cells (NFKb) remained significant. Conclusion: Although multiple factors can influence symptom severity, genetic variation may play a part. The early identification of men likely to develop severe symptoms during the course of their prostate cancer could theoretically enable symptoms to be managed more aggressively from an early stage. These preliminary findings need to be replicated in a larger cohort of men with CRPC.
- 18 December 2025
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 16 (2) , 393-400
Genomic variation in symptom expression in castrate-resistant prostate cancer
Objectives: Men with castrate-resistant prostate cancer (CRPC) suffer from symptoms related to both their disease and its treatment with marked variation between individuals with respect to symptom expression. This study aimed to determine whether genetic variation in cytokine expression is associated with symptom severity. Methods: An exploratory prospective, longitudinal consecutive patient cohort study was undertaken across two Queensland sites. Patient characteristics including tumour burden and current treatment were collected at baseline. Symptom severity was assessed 3–4 weekly for up to 6 assessments, with blood taken for genetic analysis once only during the study. Cytokine gene variants of each participant were assessed using a panel of single nucleotide polymorphisms (SNPs) most described in the literature. Results: Of the 66 participants, 27/66 (41%) had a low, and 39/66 (59%) a high tumour burden. Symptom severity was not related to tumour burden or patient characteristics. Of the 142 SNPs analysed from 62 participants, 15 SNPs from 7 genes were significantly associated with symptom severity. After Benjamini-Hochberg adjustment, SNPs rs2069772 from Interleukin-2 (IL2) and rs230494 from Nuclear Factor kappa-light-chain-enhancer of activated B cells (NFKb) remained significant. Conclusion: Although multiple factors can influence symptom severity, genetic variation may play a part. The early identification of men likely to develop severe symptoms during the course of their prostate cancer could theoretically enable symptoms to be managed more aggressively from an early stage. These preliminary findings need to be replicated in a larger cohort of men with CRPC.
- Open Access
- 1 January 2025
- Published by SAGE Publications in Palliative Care and Social Practice
- Vol. 19
Is there a role for hypnosis in palliative care?
Hypnosis has gained popular interest over the last few decades and has become increasingly subject to research study. Evidence of benefit in the palliative care setting is largely lacking, but it has been shown to have a favourable impact on psychological symptoms, especially anxiety, as well as chronic pain conditions. As a personalised approach, hypnotherapy is an excellent example of individual-centred care. Moreover, in the absence of significant adverse effects, it offers great promise as a complementary therapy.
- 1 January 2025
- Published by SAGE Publications in Palliative Care and Social Practice
- Vol. 19
Open AccessIs there a role for hypnosis in palliative care?
Hypnosis has gained popular interest over the last few decades and has become increasingly subject to research study. Evidence of benefit in the palliative care setting is largely lacking, but it has been shown to have a favourable impact on psychological symptoms, especially anxiety, as well as chronic pain conditions. As a personalised approach, hypnotherapy is an excellent example of individual-centred care. Moreover, in the absence of significant adverse effects, it offers great promise as a complementary therapy.
- Open Access
Pain Assessment for Patients with Dementia and Communication Impairment: Feasibility Study of the Usage of Artificial Intelligence-Enabled Wearables
Background: Recent studies on machine learning have shown the potential to provide new methods with which to assess pain through the measurement of signals associated with physiologic responses to pain detected by wearables. We conducted a prospective pilot study to evaluate the real-world feasibility of using an AI-enabled wearable system for pain assessment with elderly patients with dementia and impaired communication. Methods: Sensor data were collected from the wearables, as well as observational data-based conventional everyday interventions. We measured the adherence, completeness, and quality of the collected data. Thereafter, we evaluated the most appropriate classification model for assessing the detectability and predictability of pain. Results: A total of 18 patients completed the trial period, and 10 of them had complete sensor and observational datasets. We extracted 206 matched records containing a 180 min long data segment from the sensor’s dataset. The final dataset comprised 153 subsets labelled as moderate pain and 53 labelled as severe pain. After noise reduction, we compared the recall and precision performances of 14 common classification algorithms. The light gradient-boosting machine (LGBM) classifier presented optimal values for both performances. Conclusions: Our findings tended to show that electrodermal activity (EDA), skin temperature, and mobility data are the most appropriate for pain detection.
Open AccessPain Assessment for Patients with Dementia and Communication Impairment: Feasibility Study of the Usage of Artificial Intelligence-Enabled Wearables
Background: Recent studies on machine learning have shown the potential to provide new methods with which to assess pain through the measurement of signals associated with physiologic responses to pain detected by wearables. We conducted a prospective pilot study to evaluate the real-world feasibility of using an AI-enabled wearable system for pain assessment with elderly patients with dementia and impaired communication. Methods: Sensor data were collected from the wearables, as well as observational data-based conventional everyday interventions. We measured the adherence, completeness, and quality of the collected data. Thereafter, we evaluated the most appropriate classification model for assessing the detectability and predictability of pain. Results: A total of 18 patients completed the trial period, and 10 of them had complete sensor and observational datasets. We extracted 206 matched records containing a 180 min long data segment from the sensor’s dataset. The final dataset comprised 153 subsets labelled as moderate pain and 53 labelled as severe pain. After noise reduction, we compared the recall and precision performances of 14 common classification algorithms. The light gradient-boosting machine (LGBM) classifier presented optimal values for both performances. Conclusions: Our findings tended to show that electrodermal activity (EDA), skin temperature, and mobility data are the most appropriate for pain detection.
- Open Access
- 4 January 2024
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 25 (3) , 364-375
Hypnosis for Symptom Management in Adult Cancer Patients: What is the Evidence?
Opinion Statement: As a palliative care specialist and a hypnotherapist, I use therapeutic communication and conversational hypnosis daily in my patient – doctor relationship. Formal hypnotherapy sessions are integrated in my practice whenever patients are open or wish for such an approach in relation to a specific symptom, for better overall management of their disease burden and/or enhanced well-being. Although hypnosis has been used for centuries in medical practice and for thousands of years in healing practices in ancient cultures all over the world, the evidence remains scarce. Nevertheless, in the last 10 years several randomised controlled trials have been conducted, building up an evidence base. In contrast to most oncological treatments, hypnotherapy is far from being considered evidence-based “standard care”. It is however, if practiced by a trained health care professional, almost free of side effects and therefore potentially has a very favourable benefit-to-harm ratio. The question arises whether hypnotherapy will ever become a standard of care intervention? This seems unlikely since its efficacy may be influenced by the patient’s belief in hypnosis and compliance to therapy. Furthermore, a fundamental necessity is a personalised approach that moves hypnotherapy more into the category of individual-centred care rather than standard care.
- 4 January 2024
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 25 (3) , 364-375
Open AccessHypnosis for Symptom Management in Adult Cancer Patients: What is the Evidence?
Opinion Statement: As a palliative care specialist and a hypnotherapist, I use therapeutic communication and conversational hypnosis daily in my patient – doctor relationship. Formal hypnotherapy sessions are integrated in my practice whenever patients are open or wish for such an approach in relation to a specific symptom, for better overall management of their disease burden and/or enhanced well-being. Although hypnosis has been used for centuries in medical practice and for thousands of years in healing practices in ancient cultures all over the world, the evidence remains scarce. Nevertheless, in the last 10 years several randomised controlled trials have been conducted, building up an evidence base. In contrast to most oncological treatments, hypnotherapy is far from being considered evidence-based “standard care”. It is however, if practiced by a trained health care professional, almost free of side effects and therefore potentially has a very favourable benefit-to-harm ratio. The question arises whether hypnotherapy will ever become a standard of care intervention? This seems unlikely since its efficacy may be influenced by the patient’s belief in hypnosis and compliance to therapy. Furthermore, a fundamental necessity is a personalised approach that moves hypnotherapy more into the category of individual-centred care rather than standard care.
- 22 June 2023
- Published by Springer Nature
- p. 217-227
Pain
- 30 September 2022
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 25 (10) , 1606-1609
“I Am Not the Same Man…”: A Case Report of Management of Post-COVID Refractory Dyspnea
The SARS-CoV-2 pandemic brings with it a significant number of post-COVID symptoms, including persistent dyspnea and neuropsychological sequelae. The palliative approach in the treatment of these refractory symptoms is effective and widely applicable in different settings. We report the case of a patient with refractory dyspnea admitted to a specialized palliative care unit with a very poor prognosis. The application of different tools of the palliative approach proved to be effective: a detailed advanced care planning and open communication, the respect for the patient's wishes and optimal use of his resources—the salutogenesis — an adaptation of the rhythm of care to that of the patient. The patient was then discharged for rehabilitation, and finally returned home.
- 30 September 2022
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 25 (10) , 1606-1609
“I Am Not the Same Man…”: A Case Report of Management of Post-COVID Refractory Dyspnea
The SARS-CoV-2 pandemic brings with it a significant number of post-COVID symptoms, including persistent dyspnea and neuropsychological sequelae. The palliative approach in the treatment of these refractory symptoms is effective and widely applicable in different settings. We report the case of a patient with refractory dyspnea admitted to a specialized palliative care unit with a very poor prognosis. The application of different tools of the palliative approach proved to be effective: a detailed advanced care planning and open communication, the respect for the patient's wishes and optimal use of his resources—the salutogenesis — an adaptation of the rhythm of care to that of the patient. The patient was then discharged for rehabilitation, and finally returned home.
- 12 May 2021
- Published by CAIRN.INFO in Revue internationale de soins palliatifs
- Vol. 35 (2) , 68-70
Atelier 5 – Collaboration en gériatrie
- 12 May 2021
- Published by CAIRN.INFO in Revue internationale de soins palliatifs
- Vol. 35 (2) , 68-70
Atelier 5 – Collaboration en gériatrie
- 1 September 2017
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 54 (3) , e1-e3
Symptom Clusters in Men With Castrate-Resistant Prostate Cancer
- 1 September 2017
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 54 (3) , e1-e3
Symptom Clusters in Men With Castrate-Resistant Prostate Cancer
- 2 September 2015
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 8 (4) , 475-484
Advance directives and end-of-life decisions in Switzerland: role of patients, relatives and health professionals
Background Little is known in Europe about end-of-life (EOL) decisions and advance directives (AD), particularly in patients with severe advanced disease. Switzerland is a multicultural and multilingual federal country and has the particularity of being divided into four linguistic and cultural regions Objective To understand better in different regions of Switzerland which specific patient's characteristics could have an impact on their decision to complete AD or not. Design/setting/participants Prospective study conducted in four palliative care units. Patients with an advanced oncological disease, fluent in French, German or Italian and with a Mini-Mental State Examination >20 were included. Demographic data, symptom burden (Edmonton Symptom Assessment System, ESAS; Hospital Anxiety and Depression Scale, HADS) and spiritual well-being (Functional Assessment of Chronic Illness Therapy-Spiritual well-being, FACIT-sp) have been assessed. A structured questionnaire has been completed by patients, their relatives and health professionals. Results 143 patients were included (mean age 68.3 years; 62 male). 41 completed ADs. No particular features were associated with the completion of ADs. Most patients were satisfied with the medical information received. A third of them were not worrying about their future, especially those living in the German-speaking part. Should they become unable to communicate, 87 expected their relative to transmit their own wishes, but only 38 had spoken recently with them about what they wanted. 23 of the 69 included relatives would like to play a more active role in decision-making. Conclusions These results illustrate the fact that terminally ill patients wish to be active in decision-making, but only seldom transmit their wishes to their relative or complete a written document. The discussion about ACP should be defined according to the particularity of each region and the role of healthcare professionals’ attitudes towards ADs, but we should also be creative and find other ways to promote shared decision-making.
- 2 September 2015
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 8 (4) , 475-484
Advance directives and end-of-life decisions in Switzerland: role of patients, relatives and health professionals
Background Little is known in Europe about end-of-life (EOL) decisions and advance directives (AD), particularly in patients with severe advanced disease. Switzerland is a multicultural and multilingual federal country and has the particularity of being divided into four linguistic and cultural regions Objective To understand better in different regions of Switzerland which specific patient's characteristics could have an impact on their decision to complete AD or not. Design/setting/participants Prospective study conducted in four palliative care units. Patients with an advanced oncological disease, fluent in French, German or Italian and with a Mini-Mental State Examination >20 were included. Demographic data, symptom burden (Edmonton Symptom Assessment System, ESAS; Hospital Anxiety and Depression Scale, HADS) and spiritual well-being (Functional Assessment of Chronic Illness Therapy-Spiritual well-being, FACIT-sp) have been assessed. A structured questionnaire has been completed by patients, their relatives and health professionals. Results 143 patients were included (mean age 68.3 years; 62 male). 41 completed ADs. No particular features were associated with the completion of ADs. Most patients were satisfied with the medical information received. A third of them were not worrying about their future, especially those living in the German-speaking part. Should they become unable to communicate, 87 expected their relative to transmit their own wishes, but only 38 had spoken recently with them about what they wanted. 23 of the 69 included relatives would like to play a more active role in decision-making. Conclusions These results illustrate the fact that terminally ill patients wish to be active in decision-making, but only seldom transmit their wishes to their relative or complete a written document. The discussion about ACP should be defined according to the particularity of each region and the role of healthcare professionals’ attitudes towards ADs, but we should also be creative and find other ways to promote shared decision-making.